Hims and Hers (HIMS) PT Raised to $61 at Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
February 24, 2025 4:05 PM ESTRevenue of $1.5 billion, up 69% year-over-year in 2024
Net income of $126 million; Adjusted EBITDA of $177 million in 2024
Subscribers grew to 2.2 million, up 45% year-over-year in 2024
Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (Hims & Hers or the Company, NYSE: HIMS), the leading health and wellness platform, today announced financial results for... More
Hims & Hers Acquires US-based Peptide Facility
February 21, 2025 9:00 AM ESTThe acquisition will strengthen the long-term durability of the companys domestic supply chain, helping to ensure Americans can consistently access personalized medications
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the companys long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment... More
